Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.

Cancer research - 1 Dec 2008

Rokavec Matjaz, Schroth Werner, Amaral Sandra M C, Fritz Peter, Antoniadou Lydia, Glavac Damjan, Simon Wolfgang, Schwab Matthias, Eichelbaum Michel, Brauch Hiltrud

Abstract excerpt

Tamoxifen therapy is a standard in the treatment of estrogen receptor (ER)-positive breast cancer; however, its efficacy varies widely among patients. In addition to interpatient differences in the tamoxifen-metabolizing capacity, there is growing evidence that crosstalk between ER and growth factor signaling contributes to tamoxifen resistance. We focused on TC21, a member of the Ras superfamily, to investigate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to DNA, Neoplasm

Share to Electrophoresis

Share to Estrogen Receptor alpha

Share to Monomeric GTP-Binding Proteins

Share to Tamoxifen

Source

Identifiers

PMID: 19047159
DOI: 10.1158/0008-5472.CAN-08-0247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.PMID 19047159Read ↗

Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.Semantic proximity Read ↗

The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort.Semantic proximity Read ↗

TCF21 genetic polymorphisms and breast cancer risk in Chinese women.Semantic proximity Read ↗

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.Semantic proximity Read ↗

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.Semantic proximity Read ↗

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.Semantic proximity Read ↗

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifenSemantic proximity Read ↗

Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism.Semantic proximity Read ↗

Tamoxifen-stimulated growth of breast cancer due to p21 lossSemantic proximity Read ↗

Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cellsSemantic proximity Read ↗

A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study.Semantic proximity Read ↗

Ras-related TC21 is activated by mutation in a breast cancer cell line, but infrequently in breast carcinomas in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.